Efficiency of mesenchymal stem cell therapy in ulcerative colitis as assessed by the morphology of colon mucosa (original) (raw)
Related papers
International immunopharmacology, 2017
Inflammatory bowel disease (IBD) is an autoimmune-inflammatory disorder that results in inflammatory responses in individuals who are genetically susceptible. Uncontrolled inflammation in Crohn's disease (CD) or Ulcerative colitis (UC) affects the patient quality of life. Current therapies are not completely effective while cell therapy, especially the treatment with mesenchymal stem cells (MSCs) absorb lots of attention due to its immunomodulatory properties. So, we examined the effects of mesenchymal stem cells-conditioned medium (MSC-CM) in the experimental model of acute colitis. MSC-CM was isolated from C57Bl/6 male mice and stored. The acute colitis induction in C57BL/6 mice was performed by dissolving dextran sulfate sodium (DSS) in drinking water and then CM injected intraperitoneally. During the study body weight changes, bleeding, stool consistency, disease activity index (DAI), mortality rate, weight and length of the colon and histopathological analysis were recorded...
Journal of clinical biochemistry and nutrition, 2015
Mouse bone marrow-derived clonal mesenchymal stem cells (mcMSCs), which were originated from a single cell by a subfractionation culturing method, are recognized as new paradigm for stem cell therapy featured with its homogenous cell population. Next to proven therapeutic effects against pancreatitis, in the current study we demonstrated that mcMSCs showed significant therapeutic effects in dextran sulfate sodium (DSS)-induced experimental colitis model supported with anti-inflammatory and restorative activities. mcMSCs significantly reduced the disease activity index (DAI) score, including weight loss, stool consistency, and intestinal bleeding and significantly increased survival rates. The pathological scores were also significantly improved with mcMSC. We have demonstrated that especial mucosal regeneration activity accompanied with significantly lowered level of apoptosis as beneficiary actions of mcMSCs in UC models. The levels of inflammatory cytokines including TNF-α, IFN-γ,...
Journal of Translational Science, 2016
Adult marrow-derived mesenchymal stem cells (MSCs) have anti-inflammatory properties in patients with Inflammatory Bowel Disease (IBD), but systemic delivery is associated with safety concerns. Whether topical delivery of MSCs would provide similar efficacy to systemic administration is unknown. To compare topicallydelivered MSCs to systemic asministration, and non-MSC therapy, in animal model of colitis. Trinitrobenzenesulfonic acid (TNBS) colitis was induced in Wistar rats. Topical MSCs were compared to intravenous MSCs, adalimumab, infliximab and control in this model. Serial measurements of clinical criteria were used (i.e., weight, stool characteristics), and serum interleukin 6 (IL-6) and TNF measurements and macroscopic and microscopic scores were used to evaluate treatment efficacy. Topical and intravenous stem cell treatments, significantly prevented weight loss in TNBS mice on day 3 of colitis. There was greater evidence of a difference mainly on the third day (p<0.001). IV or PR stem cells also reduced serum IL-6 and TNF levels to similar levels to those of anti-TNF treated animals. In the intestinal tract, stem-cell treatment ameliorated the microscopic and macroscopic damage caused by TNBS. Rectal-delivered stem cells produced similar results to IV-delivered cells. This study demonstrates that rectal stem cells can treat colitis in an animal model to a similar extent to IV stem cells and systemic anti-TNF therapies. The mechanisms of this effect warrants further study. Objectives This study aims to assess the applicability and the results of mesenchymal stem cell implantation in animals submitted to
Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats
Scientific reports, 2018
Owing to the recent progress in regenerative medicine technology, clinical trials that harnessed the regeneration and immune modulation potentiality of stem cells for treating IBD have shown promising results. We investigated the feasibility and utility of intraluminal endoscopic transplantation of rat MSC sheets in murine models of experimental colitis for targeted delivery of stem cells to lesions. We isolated adipose-derived mesenchymal stem cells (AD-MSC) and bone marrow-derived mesenchymal stem cells (BM-MSC) from EGFP-transgenic rats and fabricated the cells in sheet forms using temperature-responsive culture dishes. The MSC sheets were endoscopically transplanted to the inflamed area in electrocoagulation and DNBS colitis model. The effect of the transplantation was verified using endoscopic scoring and histological analysis. In the electrocoagulation model, the AD-MSC group showed significantly decreased ulcer size in the transplanted regions. In the DNBS colitis model, the ...
Mesenchymal Stem Cells to treat Inflammatory Bowel Disease
Journal of medical-clinical research & reviews, 2022
Inflammatory bowel disease (IBD) is a term for two chronic conditions. These diseases are Crohn's disease and ulcerative colitis that are both identified by inflammation in the gastrointestinal (GI) tract. Crohn's disease can occur anywhere in the digestive tract. In contrast to that, ulcerative colitis is limited to just the colon. Along with that, Crohn's disease can have gaps of healthy tissue in between inflamed areas while ulcerative colitis has no healthy gaps amongst inflamed areas. Factors such as stress and diet have been proven to aggravate symptoms of inflammatory bowel diseases. Symptoms include abdominal pain, fatigue, joint pain, and anemia. Crohn's disease and ulcerative colitis can cause ulcers, bowel obstruction, fistulas, malnutrition, and many other health conditions. There is also increased risk of cancer and blood clots. These factors make efficient treatments crucial for the disease. Researchers have tested stem cells and their efficiency to treat inflammatory bowel diseases. This is because stem cells are cells that have not become specialized. This allows for the cell to produce new cells or replaces specialized damaged or lost cells. Mesenchymal stem cells (MSCs) have been used in both human and animal research to treat inflammatory bowel disease. This type of stem cell can differentiate into various tissue types. Mesenchymal stem cells also contain anti-inflammatory and antifibrotic properties making it ideal to treat inflammation in autoimmune diseases. Mesenchymal stem cells have shown to be capable of treating inflammatory bowel disease due to their regenerative capabilities, immune-suppressive properties, and anti-inflammatory components. This has been seen in animal and human patients by achieving an increase in quality of life through results like reduced inflammation, complete remission, and reduced health complications making it an ideal treatment to continue and research for inflammatory bowel disease.
Mesenchymal Stem Cells and Their Use in Inflammatory Bowel Illness
International Journal of Engineering and Applied Computer Science (IJEACS), 2022
New pharmacological, surgical, and endoscopic therapies have recently been developed to treat IBD. Among them, stem cell treatment is still in its early stages, despite the fact that multiple studies show that stem cell therapy's immunomodulatory function may decrease inflammation and tissue harm in IBD patients. Intralesional transplantation of autologous or allogeneic MSCs can be deemed a safe and successful therapeutic method for mending perianal fistulas in CD patients, according to this research, which analyses randomized clinical trials and their potential relevance. We did a thorough search of the literature to find research that looked into the function of stem cell treatment in IBD. Since multiple clinical trials have documented exacerbations of IBD following intravenous infusion of MSCs, this literature raises safety concerns about the systemic administration of MSCs.
Stem Cells Translational Medicine
Therapy with mesenchymal stromal cells (MSCs) has shown promise in inflammatory bowel disease—leveraging their immunosuppressive and regenerative properties. However, the potential immunogenic complications of allogenic MSCs sourced from different tissues raise concern. Thus, we assessed the fitness and functionality of autologous intestinal MSCs as a potential platform for cellular therapy. Mucosal biopsy-derived MSCs from Crohn’s disease (n = 11), ulcerative colitis (n = 12), and controls (n = 14) were analyzed by microscopy and flow cytometry for doubling-time, morphology, differentiation potential, and immunophenotype. Gene expression, cell-subtype composition, along with surface marker and secretome changes after IFN-γ priming were measured by bulk and single-cell RNA sequencing coupled with a 30-plex Luminex panel. MSCs expanded ex vivo demonstrate canonical MSC markers, similar growth kinetics, and tripotency regardless of the patient phenotype. Global transcription patterns ...
Inflammation, 2019
Acute inflammatory bowel disease (AIBD) is a wide clinical entity including severe gastrointestinal pathologies with common histopathological basis. Epidemiologically increasing diseases, such as necrotizing enterocolitis (NEC), gastrointestinal graft versus host disease (GVHD), and the primary acute phase of chronic inflammatory bowel disease (CIBD), exhibit a high necessity for new therapeutic strategies. Mesenchymal stem cell (MSC) cellular therapy represents a promising option for the treatment of these diseases. In our study, we comparatively assess the efficacy of human MSCs derived from bone marrow (BM), umbilical cord blood (UCB), human embryonic stem cells (ESCs), or human-induced pluripotent stem cells (iPSCs) in a mouse model of chemically induced acute enterocolitis.
Citation: Emanuele Sinagra (2013) Mesenchimal Stem Cells in Inflammatory Bowel Diseases: Clinical Evi-dences And Potential Insights for The Clinicians 1:301 Abstract Mesenchymal stem cells (MSCs) have been used experimentally and clinically in the treatment of a wide variety of pathologies. MSCs can be safely transplanted in autologous and allogeneic ways as they are non-immunogen-ic, and consequently represent a therapeutic option for refractory connective tissue diseases, fibrosing diseases like scleroderma and fistulizing colitis like in Crohn's disease (CD). The immunomodulatory properties of MSCs have already shown promise when used as therapy for otherwise medically refractory CD. Accumulating evidence suggests that these properties may also be exploited in the treatment of several other conditions. The currently available experimental and clinical data indicate that, similar to previously obtained data in the setting of HSCT, MSC treatment for IBD is feasible and safe. Aim of this review is to analyze the pathophysiologi-cal insights for the use of MSCs in inflammatory bowel diseases, and to summarize the clinical evidences about the efficacy and safety of stem cell therapy in such disorders.